Tuberculosis (TB) Drugs/Therapeutics Market Size, Share & Trends Analysis Report by Disease Type (Active TB, Latent TB), By Therapy (First-Line, Second-Line), By Region, Competitive Landscape, And Segment Forecasts, 2018 - 2025

Industry Insights

The global tuberculosis drugs/therapeutics market size was estimated at USD 915.6 million in 2016 and is anticipated to exhibit a CAGR of 5.2% over the forecast period. High incidence of drug susceptible (DS) tuberculosis (TB), rise in multi-drug resistant (MDR) TB cases, and increase in R&D efforts toward drug development are some of the factors anticipated to fuel market growth.

Globally, low patient adherence to medication remains a concern underlying the occurrence of MDR TB, with few effective drug alternatives in the market. This wave of antimicrobial drug resistance in Mycobacterium TB strains has prompted a worldwide initiative through WHO-led programs such as Directly Observed Therapy (DOT). Moreover, collaborations among international organizations, such as Unitaid, WHO, UNICEF, and TB Alliance, focused on development of shorter treatment regimens to fight drug resistance is addressing unmet medical needs, which is expected to drive market growth.

Apart from international support, high-risk countries are undertaking national efforts to reduce disease burden. For instance, the Chinese government obtained financial aid through a partnership with the Bill & Melinda Gates Foundation to enhance detection and treatment of TB. The foundation supported the initiative through a grant of USD 33 million for five years from 2009-2014.

Disease Type Insights

Based on disease type, the market is segmented into active and latent TB. The active TB (ATB) segment dominated the market in 2016 due to growing incidence of DS and MDR TB cases, which can be attributed to incomplete treatment patterns in high-risk countries. According to the Centers for Disease Control and Prevention (CDC), globally, 9 million people contract active TB on an annual basis.

While ATB holds central focus in this market, established economies with low TB risk but high immigrant flow and population mobility are emphasizing on treatment for latent TB infection (LTBI) cases.

Therapy Insights

Based on therapy, the tuberculosis therapeutics market is segmented into first-line therapy and second-line therapy. Second-line therapy drugs dominated the market with a 60.4% share in 2016. Increasing incidence of MDR TB, rising national surveillance efforts, and global initiatives through WHO and Global Drug Facility (GDF)-led programs have greatly supported the growth of this segment.

According to WHO, in 2016, 600,000 people were diagnosed with MDR-TB, 240,000 people died from the condition, and 8,000 patients tested positive for Extensively Drug-Resistant (XDR) TB. Therefore, surge in drug-resistant disease cases has fueled the demand for and uptake of second-line therapy. The cost intensive structure of MDR TB drugs is also responsible for the segment’s large revenue share in the overall market.

Regional Insights

Asia Pacific dominated the market in 2016 by accounting for a 57.4% share. This can be attributed to high incidence of the disease, increasing prevalence of HIV-TB co-infection, rising population awareness regarding hazards of medication compliance, and improving healthcare infrastructure. China and India are strong contributors in terms of API manufacturing for the APAC market.

Europe and North America are expected to grow at a rapid pace over the forecast period. Europe hosts 9 countries viewed as high-risk nations that witness an upward trend in MDR and XDR tuberculosis incidence rates. The number of new MDR-TB cases is highest in the region as reported by WHO, with 71,000 new and retreated cases reported in 2016. Incomplete treatment is the underlying factor behind the surge in drug resistant form of the disease.

Although North America reports a low DS tuberculosis incidence and prevalence, a higher immigrant population calls for greater focus on LTBI screening initiatives. Efforts to check spread of the latent disease form have increased in U.S. and Canada, where a high percentage of foreign population is detected. This is likely to boost the market for latent tuberculosis drugs in the region.

Tuberculosis Drugs/Therapeutics Market Share Insights

Key market contributors include Johnson & Johnson (J&J) Services, Lupin, Novartis AG, Macleods Pharmaceuticals Limited, and Otsuka Pharmaceutical Co., Ltd. Monetary support from national governments and international organizations serve as key incentives for pharmaceutical players supporting the global initiative to enable tuberculosis drug access for all.

J&J’s bedaquiline and Otsuka’s delaminid are the latest drugs available for patients with the drug-resistant form of the disease. These are more expensive than other existing alternatives in the market. However, efforts are on to increase patient access to these novel drugs. In 2015, Janssen collaborated with the United States Agency for International Development and the Global Drug Facility (GDF) to provide 30,000 drug courses in low- and middle-income countries as part of its donation program.

Mergers, acquisitions, and product launches are other factors likely to boost the market during the forecast period. In July 2013, Sequella acquired worldwide rights to Pfizer’s sutezolid. It is an oxazolidinone antibiotic drug currently in phase II for treatment of TB. As per clinical trial data, this drug has the potential to improve the efficacy of treatment regimens while shortening therapy durations.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels, and provides an analysis on latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global tuberculosis drugs/therapeutics market report on the basis of disease type, therapy, and region:

• Disease Type (Revenue, USD Million, 2014 - 2025)

  • Active TB

  • Latent TB

• Therapy (Revenue, USD Million, 2014 - 2025)

  • First-Line Therapy

  • Second-Line Therapy

• Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • France

    • Germany

  • Asia Pacific

    • China

    • India

    • Philippines

  • Latin America

    • Brazil

    • Mexico

    • Africa

  • South Africa

    • Nigeria